Arrhythmogenic right-ventricular cardiomyopathy/dysplasia (ARVC/D) is a rare disease, affecting 1:5000 patients in the general population. As ARVC/D causes sudden death, diagnosis is often only post-mortem. Currently, ARVC/D treatment is limited to a symptomatic approach with a combination of beta-blockers to stabilize the heart rhythm and an implanted pacemaker or defibrillator to prevent sudden cardiac death.